Barclays maintains Viatris at Overweight, raises price target to $25 from $22

Barclays kept its Overweight rating on Viatris and increased its price target to $25 from $22, suggesting a 20.1% upside from the Nov 13 close of $20.82, according to the bank.

Original reporting
Published Nov 16, 2026, 3:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 4:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Viatris at Overweight, raises price target to $25 from $22 — source image
Decision brief

The 30-second read

$VTRSBullishMed
01

Why it matters

The upgrade may attract short-term buying and support price appreciation.

02

Market read

A modest analyst upgrade that could prompt modest buying activity in Viatris.

03

What to watch

Potential competitive pressures and pipeline risks not addressed in the note.

Relevance 7/10Novelty 6/10Timing: today

Background

Barclays' analyst team adjusted its valuation model for Viatris, reflecting improved expectations.

Company-level read

Ticker impact

$VTRSBullishHigh confidence
Context

Barclays raised its price target on Viatris to $25 from $22, indicating a bullish outlook.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

The new target implies a 20% upside from the current price, prompting buying interest.

Market effects

May lift sentiment in the generic pharmaceuticals sector.

US market focus, limited regional effect.

Low global impact beyond Viatris investors.

Counterpoint

Target raise could be premature if earnings miss expectations.

Key entities

  • Barclays

    Equity research firm issuing the price target upgrade.

Related articles

$VTRSMedAI 8/10

Viatris Completes Acquisition of Pacira BioSciences

Viatris Inc. (VTRS) completed its acquisition of Pacira BioSciences (PCRX) for $36.50 per share. The deal, announced in October, aims to strengthen Viatris's U.S. pain management business. Pacira's shares will be delisted from Nasdaq, and Viatris expects the acquisition to add $90M-$100M in revenue for the rest of 2026.

$VTRSMed

Viatris and Innovata seek leave to appeal court order on HIV drug tender

Viatris and Innovata seek to appeal a court ruling that invalidated their contracts to supply HIV drugs to South Africa, worth R1.67bn and R1.575bn respectively. The court found their manufacturing licenses had expired during the bidding process. Both companies argue their disqualification was unjustified due to pending license renewals and valid import licenses.

$VTRSHighAI 8/10

VTRS Q3 2026 deep dive: new product launches and Pacira acquisition shape outlook

Viatris reported Q3 2026 revenue of $3.75 billion, missing estimates by 1.3%, but beat EPS and EBITDA expectations. The company raised full-year guidance for revenue, EPS, and EBITDA. Growth was driven by higher-margin products and new launches, while supply chain issues impacted some regions. The pending acquisition of Pacira BioSciences is expected to enhance EBITDA and expand product offerings.